We reviewed phase II and III trials beginning after 2010 studying preoperative therapy in
melanoma (61 trials). Compared to standard adjuvant treatment, neoadjuvant immune …

Neoadjuvant immune-checkpoint inhibition is a promising emerging treatment approach for
patients with surgically resectable macroscopic stage III melanoma. The neoadjuvant setting …

Locally advanced and metastatic melanoma have historically had poor survival outcomes.
Long-term follow-up of both targeted therapies and immune checkpoint inhibitors has …

Since the advent of effective systemic therapy, quantum changes have occurred in the
multidisciplinary management strategies used for patients with American Joint Committee on …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors
(ICI) in patients with melanoma have shown high clinical and pathologic response rates …

Background: Standard treatment for stage III melanoma is surgery followed by consideration
of adjuvant therapy. This strategy is inadequate for high-risk stage III patients who have a …

Background Patients with resected stage III and IV melanoma have a high risk of recurrence.
As the outcomes for patients with metastatic disease have improved dramatically over the …

Objective: To determine the feasibility and impact of neoadjuvant therapy (NT) in patients
who present with advanced melanoma amenable to surgical resection. Summary …

Clinical trials have demonstrated the efficacy of immunotherapy, especially checkpoint
blockade inhibitors, in the treatment of patients with metastatic melanoma. More recently …